Suppr超能文献

肝细胞癌放射治疗:证据回顾与未来机遇。

Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities.

机构信息

Department of Radiation Oncology, Princess Margaret Hospital/University of Toronto, Toronto, Ontario, Canada.

出版信息

Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):22-32. doi: 10.1016/j.ijrobp.2012.08.043. Epub 2012 Dec 6.

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of global cancer death. Curative therapy is not an option for most patients, often because of underlying liver disease. Experience in radiation therapy (RT) for HCC is rapidly increasing. Conformal RT can deliver tumoricidal doses to focal HCC with low rates of toxicity and sustained local control in HCC unsuitable for other locoregional treatments. Stereotactic body RT and particle therapy have been used with long-term control in early HCC or as a bridge to liver transplant. RT has also been effective in treating HCC with portal venous thrombosis. Patients with impaired liver function and extensive disease are at increased risk of toxicity and recurrence. More research on how to combine RT with other standard and novel therapies is warranted. Randomized trials are also needed before RT will be generally accepted as a treatment option for HCC. This review discusses the current state of the literature and opportunities for future research.

摘要

肝细胞癌(HCC)是全球癌症死亡的主要原因。由于基础肝病,大多数患者无法进行根治性治疗。HCC 的放射治疗(RT)经验正在迅速增加。适形 RT 可以为不适合其他局部区域治疗的局灶性 HCC 提供肿瘤杀伤剂量,且毒性反应低,局部控制持久。立体定向体部 RT 和粒子治疗已在早期 HCC 或作为肝移植桥接治疗中取得长期控制效果。RT 治疗合并门静脉血栓形成的 HCC 也有效。肝功能受损和广泛疾病的患者发生毒性反应和复发的风险增加。需要更多的研究来探讨如何将 RT 与其他标准和新型疗法相结合。在 RT 被广泛接受为 HCC 的治疗选择之前,还需要进行随机试验。本文讨论了目前的文献状况和未来研究的机会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验